CSIMarket Company Name, Ticker, Customers, else..
 
Avenue Therapeutics Inc   (NASDAQ: ATXI)
Other Ticker:  
 
 
Price: $1.8900 $0.05 2.717%
Day's High: $2.06 Week Perf: 2.16 %
Day's Low: $ 1.68 30 Day Perf: 6.78 %
Volume (M): 19,779 52 Wk High: $ 15.00
Volume (M$): $ 37,382 52 Wk Avg: $4.82
Open: $2.05 52 Wk Low: $0.09



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 2
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Avenue Therapeutics Inc
Avenue Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of an intravenous (IV) form of an opioid pain medication called Tramadol. Tramadol is commonly used to manage moderate to severe pain, and Avenue Therapeutics aims to provide a potentially safer and more effective alternative to existing IV pain medications. The company is dedicated to improving patient care and addressing the opioid crisis by offering a non-addictive solution for acute pain relief. Avenue Therapeutics is based in New York City, and it is a subsidiary of InvaGen Pharmaceuticals, a global pharmaceutical company.


   Company Address: 1111 Kane Concourse, Suite 301 Bay Harbor Islands 33154 FL
   Company Phone Number: 652?4500   Stock Exchange / Ticker: NASDAQ ATXI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AVDL      % 
CARA      % 
DRRX      % 
EVOK      % 
MRNS      % 
NBY      % 
• View Complete Report
   



Stocks on the Move

Navigating the Volatile Waters of Biotech Investment A Focus on Avenue and Protagenic Therapeutics

Published Mon, Aug 5 2024 3:55 PM UTC

In the world of biotech investments, dynamic share performance can often reflect not just the inherent qualities of the companies involved but also the broader market sentiments and strategic decisions that shape investor confidence. Recent news surrounding Avenue Therapeutics Inc. (ATXI) and Protagenic Therapeutics (PTIX) has highlighted fluctuating market conditions and th...
Stocks on the Move

Avenue Therapeutics Navigating Challenges and Seizing Opportunities in the Pharmaceutical Market

Published Tue, Jun 25 2024 2:03 PM UTC

In recent days, several significant events have unfolded in the pharmaceutical industry, particularly surrounding Avenue Therapeutics Inc. This article aims to analyze and discuss these events in order to shed light on the current status and future prospects of the company. Additionally, we will delve into the overall performance of Avenue Therapeutics within the healthcare ...
Clinical Study

Avenue Therapeutics Nears Promising Milestone in Revolutionary Clinical Trial for Kennedy's Disease: AJ201 Shows Potential for Treating Spinal and Bulbar Muscular Atrophy

Published Thu, May 16 2024 12:30 PM UTC

Avenue Therapeutics, a pioneering biopharmaceutical company, has announced an exciting update in the development of a groundbreaking treatment for Spinal and Bulbar Muscular Atrophy (SBMA), commonly known as Kennedy s Disease. The Phase 1b/2a clinical trial of their innovative drug candidate, AJ201, is well underway, with the last patient s last visit anticipated to occur in...
Avenue Therapeutics Inc

Avenue Therapeutics Inc Reports Operating Shortfall Improvement of $-3.708 Million in Q1 2024

Over the past 5 days, Avenue Therapeutics Inc stock has dropped by -11.31%, while the stock has seen a significant drop of -94.82% from a year before. Despite this recent decline, Avenue Therapeutics Inc stock has reached its 52-week high, showing signs of potential growth and stability in the future.
One of the reasons for this drop in stock value could be attributed to the company's recent announcement of an operating shortfall of $-3.708 million for the first quarter of 2024. While this may seem like bad news on the surface, it is actually an improvement from the operating shortfall of $-6.429 million during the same period a year ago. This improvement in financial performance has provided analysts with confidence in Avenue Therapeutics Inc, especially considering the decrease in returns from $-7.602 million in the first quarter of 2023 to $-4.349 million in the first quarter of 2024.
Stock Market Announcement

Avenue Therapeutics Inc: Navigating the Reverse Stock Split Terrain

Published Wed, Apr 24 2024 11:31 AM UTC

Avenue Therapeutics Announces Reverse Stock Split: What It Means for Investors
In a recent press release, Avenue Therapeutics Inc (Nasdaq: ATXI) announced a 1-for-75 reverse stock split of its common stock. This move, which will take effect on April 26, 2024, aims to adjust the trading price of Avenue s shares on the Nasdaq Capital Market. With the new CUSIP number of 05...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com